Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the EvolutTM ...

Medtronic's recall of embolization device has been classified most serious by the U.S. Food and Drug Administration (USFDA), ...

Cardiac electrophysiologist Dr. Jonathan Piccini says Medtronic's Define AFib study offers important lessons for other device ...

Medtronic announced today that it brought its Affera mapping and ablation system into clinical use for the first time in ...

Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Cardiac Dimensions has secured $53m in a Series E funding round to support its ongoing pivotal trial assessing the company’s ...

Medtronic has recalled embolization devices collectively linked to reports of 17 injuries and four deaths, the Food and Drug Administration said Tuesday. The recall has two elements: Medtronic is ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut� ...

Bengaluru: The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", following reports of the deaths of four patients.